Sarepta Therapeutics, Inc. SRPT Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $464.45M+92.8% | $801.28M-27.4% | $613.08M+210% | $510.6M+33.1% | $240.87M-43.6% | ||
| $188.74M-33.0% | $138.37M-45.0% | $237.92M-76.2% | $289.54M-73.1% | $281.9M-70.7% | ||
| $394.82M-40.1% | $398.23M-33.8% | $395.74M-8.9% | $527.3M+46.5% | $659.37M+74.1% | ||
| $174.87M-3.5% | $184.54M-1.8% | $198.6M-1.9% | $194.67M-4.9% | $181.16M-12.7% | ||
| $2.31B-5.0% | $2.54B-17.4% | $2.72B+1.4% | $2.66B-1.0% | $2.43B-1.3% | ||
| $336.24M-6.8% | $345.13M+1.4% | $358.94M+17.4% | $371.86M+34.6% | $360.59M+44.6% | ||
| $3.18B-8.3% | $3.35B-15.5% | $3.49B-3.0% | $3.68B+7.5% | $3.47B+7.5% | ||
| $70.38M-54.9% | $280.84M+31.0% | $94.02M-20.8% | $136.7M+27.3% | $156.11M+70.5% | ||
| $116.04M+159% | $443.4M+240% | $485.45M+282% | $395.43M+224% | $44.86M-59.9% | ||
| —— | —— | —— | —— | —— | ||
| $499.16M-17.6% | $1.1B+49.7% | $921.43M+31.7% | $919.95M+33.6% | $605.59M-0.5% | ||
| $1.67B-27.9% | $2.21B-9.3% | $2.17B-8.6% | $2.32B-1.1% | $2.32B+2.6% | ||
| $11K+10.0% | $11K+10.0% | $11K+10.0% | $10K0.0% | $10K+11.1% | ||
| -$4.55B+2.4% | -$4.88B-15.8% | -$4.64B-6.2% | -$4.46B-1.3% | -$4.66B-5.6% | ||
| $1.51B+31.7% | $1.14B-25.3% | $1.32B+8.1% | $1.36B+26.0% | $1.14B+18.9% | ||
| $3.18B-8.3% | $3.35B-15.5% | $3.49B-3.0% | $3.68B+7.5% | $3.47B+7.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Sarepta Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 4.63 — current assets exceed current liabilities.
- Where does Sarepta Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.